Articles On Rhythm Biosciences (ASX:RHY)

ASX slips just 12.3 points, remaining near all-time high Healthcare leads losses as Trump raises tariff spectre Gains in gold and consumer discretionary soften losses   Profit takers stay their hands When markets hit new closing highs, it...

Gold stocks drive gains with index climbing 3.3pc ASX hits new record close at 8843 points Broad market strength with 10 of 11 sectors up Solid gains supported by gold It was another picturesque day of trading on the ASX today, rising st...

ASX surges 1.23pc on broad strength 11 of 11 sectors positive throughout trade ASX just 0.07pc off all-time high Market powers higher with all cylinders firing The ASX moved to its own tune today, making strong gains in the first hour an...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights ASX closes flat despite a weak global lead Gold explorers and miners post notable gains Tech and financial sectors experience pressure The Australian share market managed to steady itself despite starting th...

ASX ends flat, overcoming difficult trading session Gold stocks lead gains with index up 3.57pc Info tech and financials slide on US market losses   ASX sticks the landing Although all indicators were pointing to a down day on the ASX to...

ColoSTAT diagnostic performance consistent across colorectal cancer I to IV stages Performance meets clinical requirements for symptomatic patient testing use case Commercialisation steps underway as ColoSTAT kit transitioned to final pro...

Imugene and Chimeric have unveiled further promising results for their Car-T immune-oncology assets Rhythm Biosciences shares soar 18% on kit validation results While investors are picky, equity dollars continue to flow   There’s a long d...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) as the company undergoes a leadership transition, with outgoing Chair Otto Buttula reflecting on his tenure. Buttula paid a crucial role in overseeing RHY’s proteomic platform expansion in...

ASX surges 1pc as Iran and Israel approach ceasefire Materials and financials lead gains, adding more than 1.8pc each Energy sector drags, shedding 3.89pc as oil slumps   ASX on the rise as missiles keep firing The ASX shot up 1% today, w...

Rhythm receives reinstatement of NATA accreditation for Genetype risk assessment portfolio Genetype is a sophisticated genetic risk assessment testing platform for various diseases Reinstatement is a key milestone for securing ColoSTAT acc...

Rhythm Biosciences has expanded its original remit of bowel cancer to diagnosing other cancers early in the piece The company late last year acquired the Genetype platform from the administrators of Genetic Technologies Rhythm is developin...

Rhythm publishes peer-reviewed study validating its next-generation colorectal cancer risk assessment model Proprietary geneType assessment enhanced and cross-validated using data from nearly 400,000 individuals in UK Biobank Next generati...

Little Green Pharma reports record revenue and a return to profits Botanix raises $48 million of debt for its anti-sweating drug, Sofdra The DNA of Genetic Technologies soon will be … financial advice   Little Green Pharma’s (ASX:LGP) Eur...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) CEO David Atkins about the company’s mission to make cancer a more treatable condition through earlier detection—starting with bowel cancer. Rhythm is developing ColoSTAT, a groundbreaking...

 Having produced more positive diagnostics results, Proteomics plans to launch its Promarker Endo device locally this year Immutep posts more positive trial results, this time for soft tissue sarcoma Broker values EBR Systems share price a...

  Rhythm successfully completes verification and validation of second-generation ColoSTAT beta assay kits Validation confirms required performance for commercialisation of simple blood test to detect bowel cancer in symptomatic patients Co...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Surgical probe steriliser Nanosonics flags robust December half numbers The biotech quarterlies are tricking in – and there’s mixed news Paradigm shares are worth twice as much as their current price, says Pitt Street Partners   Nanosonic...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

Melbourne-based bowel cancer diagnostics developer Rhythm Biosciences (ASX: RHY) has acquired the GeneType disease prediction business for $625,000 from Genetic Technologies (ASX: GTG), which entered administration last month after falling...

Rhythm Biosciences reports it has attained all key milestones for 2024 Company receives delivery of second generation ColoSTAT beta release candidate multiplex kits Rhythm has a market-entry roadmap for second generation ColoSTAT Assay wit...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Rhythm Biosciences’ new CEO Dr David Atkins is on a mission to improve early diagnosis of bowel cancer Company raises $3.5 million in a placement supported by  several  new  institutional,  professional  and  sophisticated investors Secon...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

ASX ends very modestly lower after a mixed session Newmont and Fortescue shares drop on disappointing updates WiseTech continues its slide as investors start to grumble   Aussie shares swung to a flattish close today after earlier losses...

Telix Pharmaceuticals’ brain cancer diagnostic could leapfrog over its kidney cancer assay to be its second commercialised product Rhythm Biosciences still hopes to flush the bowel cancer ‘poo test’ into history Today’s quarterly reports s...

ASX rises as banking and tech sectors lead gains Arcadium Lithium surges on potential acquisition by Rio Tinto Retail groups urge Reserve Bank to cut rates ahead of holiday sales   The ASX200 index rose by 0.7% on Monday though investors...

Medical diagnostics company Rhythm Biosciences (ASX: RHY) has confirmed that the second version of its ColoSTAT kit for the detection of colorectal cancer has shown significant outperformance on the original. Preliminary testing of 200 pati...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

ASX struggled to rise, with gains tempered by CSL and Seek CSL’s earnings and cautious forecast hurt the health sector Trump discussed policies with Musk amid a busy day for the markets   After a flat start, Aussie stocks started edging h...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The 2024 Bioshares Biotech Summit is being held in Fremantle from July 12-13 Day two’s focus is on new companies, diagnostics and those following a new direction Trends in healthcare and biotech sector a focus as investor sentiment improve...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

While most developers of health diagnosis tools scurry off to the capacious US market, Bcal is happy to use Australia as the springboard for what will be the country’s first blood-based breast cancer assay. “It’s a passion of ours to launch...

“We are honoured to have world-class, distinguished leaders in their field of Colorectal Cancer diagnostics form our CAB and look forward to their expertise and guidance in this significant commercialisation stage of ColoSTAT,” said...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  ASX200 rises by a broken fingernail and just looks flat IT gains offset by Energy losses as uranium stocks get hit hard Really peculiar bunch of small cap winners led by AVA Risk and Venture Minerals   Local markets have wavered either...

Together with the Baker Institute, Rhythm identifies best five-biomarker combination that can target the various stages of lung cancer The company used a cohort of 70 healthy and cancerous patients It will now move towards a larger s...

Rhythm Bio says biomarker findings warrant the case for new investment in R&D Dental focused SDI says product registration globally is becoming more difficult to achieve   Rhythm Bio says new R&D investment is warranted after this...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...